GINMU >
01 奈良県立医科大学 >
011 医学部 >
0112 紀要 >
01121 Journal of Nara Medical Association >
Vol.48 No.6 >
このアイテムの引用には次の識別子を使用してください:
http://hdl.handle.net/10564/401
|
タイトル: | Cis-diamminedichloroplatinumを中心とした多剤併用化学療法における腎毒性の検討 : Ⅱ. 泌尿器科悪性腫瘍症例におけるCAP療法およびM-VAC療法の腎機能に対する影響と腎機能低下症例に対するCDDPの至適投与量について |
その他のタイトル: | NEPHROTOXICITY OF CIS-DIAMMINE DICHLOROPLATINUM BASED COMBINATION CHEMOTHERAPY : Ⅱ. EFFECTS OF CAP AND M-VAC REGIMENS ON RENAL FUNCTION IN CASES WITH UROLOGICAL CANCER AND OPTIMUM DOSES OF CDDP FOR CASES WITH RENAL HYPOFUNCTION |
著者: | 林, 美樹 |
キーワード: | CAP M-VAC CDDP renal function |
発行日: | 1997年12月31日 |
出版者: | 奈良医学会 |
引用: | 奈良医学雑誌 Vol.48 No.6 p.347-357 |
抄録: | The present investigation was conducted to examine the nephrotoxicity of
CDDP based combination chemotherapy for urogenital cancer.
Group 1 included those cases who received full dose of CAP or M-VAC therapy.
Group 2 included those cases with a single kidney after unilateral nephroureterectomy
for upper urinary tract urotherial cancer.
Group 3 included those cases with renal hypofunction (S-Cr≧1.3 times of normal range
and/or Ccr < 60 ml/min).
In these three groups, renal function at 2 weeks (early phase) and 6 months (late
phase) after CAP or M-VAC therapy were examined. Parameters of renal function used
were serum Cr, serum BUN and Ccr.
All three groups showed no remarkable nephrotoxic changes after CAP or M-VAC
therapy. Thereafter all patients were divided into three groups according to Ccr levels ; less
than 40 ml/min, less than 50 ml/min, and less than 60 ml/min. Total doses of CDDP of those
three groups showed 66%, 74% and 81%, respectively.
These results suggest that optimum CDDP doses according to Ccr levels in cases with
renal hypofunction can be established. |
URI: | http://hdl.handle.net/10564/401 |
ISSN: | 04695550 13450069 |
出現コレクション: | Vol.48 No.6
|
このリポジトリに保管されているアイテムは、他に指定されている場合を除き、著作権により保護されています。
|